The meaning, measurement and modification of hypoxia in the laboratory and the clinic.
AffiliationThe Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Oxford, UK.
MetadataShow full item record
AbstractHypoxia was identified as a microenvironmental component of solid tumours over 60 years ago and was immediately recognised as a potential barrier to therapy through the reliance of radiotherapy on oxygen to elicit maximal cytotoxicity. Over the last two decades both clinical and experimental studies have markedly enhanced our understanding of how hypoxia influences cellular behaviour and therapy response. Furthermore, they have confirmed early assumptions that low oxygenation status in tumours is an exploitable target in cancer therapy. Generally such approaches will be more beneficial to patients with hypoxic tumours, necessitating the use of biomarkers that reflect oxygenation status. Tissue biomarkers have shown utility in many studies. Further significant advances have been made in the non-invasive measurement of tumour hypoxia with positron emission tomography, magnetic resonance imaging and other imaging modalities. Here, we describe the complexities of defining and measuring tumour hypoxia and highlight the therapeutic approaches to combat it.
CitationThe meaning, measurement and modification of hypoxia in the laboratory and the clinic. 2014, 26 (5):277-88 Clin Oncol
- Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
- Authors: Phillips RM
- Issue date: 2016 Mar
- The role of hypoxia-activated prodrugs in cancer therapy.
- Authors: Denny WA
- Issue date: 2000 Sep
- Tumor hypoxia in cancer therapy.
- Authors: Brown JM
- Issue date: 2007
- Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
- Authors: Martínez-Sánchez G, Giuliani A
- Issue date: 2007 Mar
- Hypoxia and cancer.
- Authors: Brahimi-Horn MC, Chiche J, Pouysségur J
- Issue date: 2007 Dec